[1]
|
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China:a single-centered, retrospective, observational study[J]. The Lancet Respiratory Medicine, 2020, 8:475-481. |
[2]
|
Ge H, Wang X, Yuan X, et al. The epidemiology and clinical information about COVID-19[J]. Eur J Clin Microbiol Infect Dis, 2020, 39:1011-1019. |
[3]
|
Doustmohammadian S, Doustmohammadian A, Momeni M. Association between thyroid disorders and COVID-19:a protocol for a systematic review and meta-analysis[J]. Thyroid Res, 2021, 14:21. |
[4]
|
Pearce EN, Farwell AP, Braverman LE. Thyroiditis[J]. N Engl J Med, 2003, 348:2646-2655. |
[5]
|
Desailloud R, Hober D. Viruses and thyroiditis:an update[J]. Virol J, 2009, 6:5. |
[6]
|
Brancatella A, Ricci D, Viola N, et al. Subacute Thyroiditis After Sars-COV-2 Infection[J]. J Clin Endocrinol Metab, 2020, 105. |
[7]
|
Caron P. Thyroiditis and SARS-CoV-2 pandemic:a review[J]. Endocrine, 2021, 72(2):326-331. |
[8]
|
Inaba H, Aizawa T. Coronavirus Disease 2019 and the Thyroid-Progress and Perspectives[J]. Frontiers in Endocrinology, 2021, 12:708333. |
[9]
|
Ippolito S, Dentali F, Tanda ML. SARS-CoV-2:a potential trigger for subacute thyroiditis?Insights from a case report[J]. J Endocrinol Invest, 2020, 43:1171-1172. |
[10]
|
Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19[J]. Nat Rev Rheumatol, 2020, 16(8):413-414. |
[11]
|
Testa A, Castaldi P, Fant V, et al. Prevalence of HCV Antibodies in Autoimmune Thyroid Disease[J]. Eur Rev Med Pharmacol Sci, 2006, 10:183-186. |
[12]
|
Sultanova A, Cistjakovs M, Gravelsina S, et al. Association of Active Human Herpesvirus-6(HHV-6) Infection With Autoimmune Thyroid Gland Diseases[J]. Clin Microbiol Infect, 2017, 23:50 e51-50 e55. |
[13]
|
Harris A, Al Mushref M. Graves'Thyrotoxicosis Following SARS-CoV-2 Infection[J]. AACE Clin Case Rep, 2021, 7:14-16. |
[14]
|
Jiménez-Blanco S, Pla-Peris B, Marazuela M. COVID-19:a cause of recurrent Graves'hyperthyroidism?[J]. J Endocrinol Invest, 2021, 44:387-388. |
[15]
|
Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease:report of two cases of Graves'disease after COVID-19[J]. J Endocrinol Invest, 2020, 43:1527-1528. |
[16]
|
Tee LY, Hajanto S, Rosario BH. Covid-19 Complicated by Hashimoto's Thyroiditis[J]. Singapore Med J, 2021, 62:265. |
[17]
|
Fliers E, Boelen A. An update on non-thyroidal illness syndrome[J]. J Endocrinol Invest, 2021, 44:1597-1607. |
[18]
|
Zou R, Wu C, Zhang S, et al. Euthyroid Sick Syndrome in Patients With COVID-19[J]. Front Endocrinol (Lausanne), 2020, 11:566439. |
[19]
|
Khoo B, Tan T, Clarke SA, et al. Thyroid Function Before, During, and After COVID-19[J]. J Clin Endocrinol Metab, 2021, 106:e803-e811. |
[20]
|
Gao W, Guo W, Guo Y, et al. Thyroid hormone concentrations in severely or critically ill patients with COVID-19[J]. J Endocrinol Invest, 2021, 44:1031-1040. |
[21]
|
Shabana TS, Anis SG, Ibrahim DM. Association between Thyroid Dysfunction and Intensive Care Unit-Acquired Weakness:A Case-Control Study[J]. Crit Care Res Pract, 2021, 2021:8889036. |
[22]
|
Wang W, Su X, Ding Y, et al. Thyroid function abnormalities in COVID-19 patients[J]. Front Endocrinol (Lausanne), 2020, 11:623792. |
[23]
|
Chen M, Zhou W, Xu W. Thyroid function analysis in 50 patients with COVID-19:a retrospective study[J]. Thyroid, 2020, 31:8-11. |
[24]
|
Lania A, Sandri MT, Cellini M, et al. Thyrotoxicosis in patients with Covid-19:the Thyrcov study[J]. Eur J Endocrinol, 2020, 183:381-387. |
[25]
|
Campi I, Bulgarelli I, Dubini A, et al. The spectrum of thyroid
function tests during hospitalization for SARS COV-2 infection[J].Eur J Endocrinol, 2021, 184:699-709. |
[26]
|
Güven M, Gültekin H. The prognostic impact of thyroid disorders on the clinical severity of COVID-19:results of single-centre pandemic hospital[J]. Int J Clin Pract, 2021, 75:e14129. |
[27]
|
Daraei M, Hasibi M, Abdollahi H, et al. Possible role of hypothyroidism in the prognosis of COVID-19[J]. Intern Med J, 2020, 50:1410-1412. |
[28]
|
Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis[J]. The Lancet Diabetes&Endocrinology, 2020, 8:739-741. |
[29]
|
Lam SD, Bordin N, Waman VP, et al. SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals[J]. Sci Rep, 2020, 10:16471. |
[30]
|
Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues[J]. Infect Dis Poverty, 2020, 9:45. |
[31]
|
Rotondi M, Coperchini F, Ricci G, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells:a clue for COVID-19-related subacute thyroiditis[J]. J Endocrinol Invest, 2021, 44:1085-1090. |
[32]
|
Moore JB, June CH. Cytokine release syndrome in severe Covid-19[J]. Science, 2020, 368:473-474. |
[33]
|
Turner AJ, Tipnis SR, Guy Jl, et al. Aceh/Ace2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ace inhibitors[J]. Can J Physiol Pharmacol, 2002, 80:346-353. |
[34]
|
Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2[J]. Antiviral Res, 2020, 177:104759. |
[35]
|
Luan J, Lu Y, Gao S, et al. A potential inhibitory role
for integrin in the receptor targeting of SARS-CoV-2[J]. J Infect, 2020, 81:318-356. |
[36]
|
Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+and CD8+T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19[J]. Nat Immunol, 2020, 21:1336-1345. |
[37]
|
Coomes EA, Haghbayan H. Interleukin-6 in Covid-19:A systematic review and meta-analysis[J]. Rev Med Virol, 2020, 30:1-9. |
[38]
|
Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19[J]. Nature, 2020, 583:437-440. |
[39]
|
Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19[J]. Sci Immunol, 2020, 5:eabd1554. |
[40]
|
Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19[J]. Nature, 2020, 584:463-469. |
[41]
|
Melo Silva Junior ML, Souza LMA, Dutra R, et al. Review on therapeutic targets for COVID-19:insights from cytokine storm[J]. Postgrad Med J, 2021, 97:391-398. |
[42]
|
Caron P. Thyroid disorders and SARS-CoV-2 infection:from pathophysiological mechanism to patient management[J]. Ann Endocrinol (Paris), 2020, 81:507-510. |
[43]
|
Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves'disease[J]. Immunol Res, 2012, 54:191-203. |
[44]
|
Kawashima A, Yamazaki K, Hara T, et al. Demonstration of innate immune responses in the thyroid gland:potential to sense danger and a possible trigger for autoimmune reactions[J]. Thyroid, 2013, 23:477-487. |
[45]
|
Hariyanto TI, Kurniawan A. Thyroid disease is associated with severe coronavirus disease 2019(COVID-19) infection[J]. Diabetes Metab Syndr, 2020, 14:1429-1430. |
[46]
|
Lisco G, De Tullio A, Jirillo E, et al. Thyroid and COVID-19:a review on pathophysiological, clinical and organizational aspects[J]. J Endocrinol Invest, 2021, 44:1801-1814. |